1832 Asset Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $126M | Buy |
641,315
+351,790
| +122% | +$67.8M | 0.12% | 137 |
|
|
2025
Q4 | $53.2M | Buy |
289,525
+275,775
| +2,006% | +$48.4M | 0.04% | 217 |
|
|
2025
Q3 | $2.11M | Sell |
13,750
-885
| -6% | -$134K | ﹤0.01% | 488 |
|
|
2025
Q2 | $2.05M | Buy |
14,635
+9,272
| +173% | +$1.3M | ﹤0.01% | 492 |
|
|
2025
Q1 | $788K | Sell |
5,363
-7,485
| -58% | -$1.08M | ﹤0.01% | 578 |
|
|
2024
Q4 | $1.68M | Sell |
12,848
-416
| -3% | -$58.2K | ﹤0.01% | 519 |
|
|
2024
Q3 | $2.07M | Sell |
13,264
-19,622
| -60% | -$3.17M | ﹤0.01% | 520 |
|
|
2024
Q2 | $5.13M | Buy |
32,886
+2,140
| +7% | +$322K | ﹤0.01% | 381 |
|
|
2024
Q1 | $4.17M | Sell |
30,746
-144,743
| -82% | -$19.2M | ﹤0.01% | 400 |
|
|
2023
Q4 | $23.6M | Buy |
175,489
+165,155
| +1,598% | +$21.5M | 0.03% | 241 |
|
|
2023
Q3 | $1.4M | Sell |
10,334
-1,057,069
| -99% | -$144M | ﹤0.01% | 539 |
|
|
2023
Q2 | $153M | Buy |
1,067,403
+169,448
| +19% | +$24.9M | 0.18% | 77 |
|
|
2023
Q1 | $125M | Sell |
897,955
-9,188
| -1% | -$1.24M | 0.18% | 86 |
|
|
2022
Q4 | $123M | Buy |
907,143
+791,328
| +683% | +$99.2M | 0.2% | 93 |
|
|
2022
Q3 | $12.7M | Sell |
115,815
-1,568,736
| -93% | -$199M | 0.02% | 329 |
|
|
2022
Q2 | $223M | Buy |
1,684,551
+167,586
| +11% | +$22M | 0.39% | 60 |
|
|
2022
Q1 | $199M | Buy |
1,516,965
+1,070,335
| +240% | +$128M | 0.28% | 78 |
|
|
2021
Q4 | $52.3M | Buy |
446,630
+126,920
| +40% | +$14.9M | 0.09% | 169 |
|
|
2021
Q3 | $37.9M | Buy |
319,710
+159,164
| +99% | +$18.5M | 0.07% | 196 |
|
|
2021
Q2 | $19.1M | Buy |
160,546
+160,390
| +102,814% | +$17.6M | 0.04% | 255 |
|
|
2021
Q1 | $15K | Sell |
156
-185,025
| -100% | -$18.6M | ﹤0.01% | 640 |
|
|
2020
Q4 | $18.6M | Buy |
185,181
+185,050
| +141,260% | +$19.6M | 0.04% | 244 |
|
|
2020
Q3 | $15K | Sell |
131
-127,579
| -100% | -$14.2M | ﹤0.01% | 631 |
|
|
2020
Q2 | $13.6M | Sell |
127,710
-11,621
| -8% | -$1.2M | 0.04% | 219 |
|
|
2020
Q1 | $12.5M | Buy |
139,331
+139,200
| +106,260% | +$13.1M | 0.05% | 213 |
|
|
2019
Q4 | $13K | Hold |
131
| – | – | ﹤0.01% | 606 |
|
|
2019
Q3 | $12K | Hold |
131
| – | – | ﹤0.01% | 627 |
|
|
2019
Q2 | $11K | Hold |
131
| – | – | ﹤0.01% | 633 |
|
|
2019
Q1 | $11K | Sell |
131
-18
| -12% | -$1.42K | ﹤0.01% | 566 |
|
|
2018
Q4 | $11K | Buy |
149
+18
| +14% | +$1.41K | ﹤0.01% | 553 |
|
|
2018
Q3 | $10K | Hold |
131
| – | – | ﹤0.01% | 592 |
|
|
2018
Q2 | $10K | Buy |
131
+56
| +75% | +$4.03K | ﹤0.01% | 568 |
|
|
2018
Q1 | $5K | Hold |
75
| – | – | ﹤0.01% | 631 |
|
|
2017
Q4 | $5K | Hold |
75
| – | – | ﹤0.01% | 644 |
|
|
2017
Q3 | $5K | Sell |
75
-775
| -91% | -$49K | ﹤0.01% | 626 |
|
|
2017
Q2 | $58K | Buy |
850
+775
| +1,033% | +$50.6K | ﹤0.01% | 543 |
|
|
2017
Q1 | $5K | Sell |
75
-247
| -77% | -$14.4K | ﹤0.01% | 662 |
|
|
2016
Q4 | $18K | Buy |
322
+247
| +329% | +$14K | ﹤0.01% | 692 |
|
|
2016
Q3 | $5K | Sell |
75
-36
| -32% | -$2.35K | ﹤0.01% | 619 |
|
|
2016
Q2 | $7K | Buy |
111
+36
| +48% | +$2.09K | ﹤0.01% | 623 |
|
|
2016
Q1 | $4K | Hold |
75
| – | – | ﹤0.01% | 577 |
|
|
2015
Q4 | $5K | Hold |
75
| – | – | ﹤0.01% | 595 |
|
|
2015
Q3 | $5K | Sell |
75
-330
| -81% | -$21.7K | ﹤0.01% | 579 |
|
|
2015
Q2 | $26K | Hold |
405
| – | – | ﹤0.01% | 562 |
|
|
2015
Q1 | $28K | Hold |
405
| – | – | ﹤0.01% | 517 |
|
|
2014
Q4 | $29K | Hold |
405
| – | – | ﹤0.01% | 526 |
|
|
2014
Q3 | $29K | Hold |
405
| – | – | ﹤0.01% | 532 |
|
|
2014
Q2 | $30K | Hold |
405
| – | – | ﹤0.01% | 524 |
|
|
2014
Q1 | $26K | Buy |
+405
| New | +$26.2K | ﹤0.01% | 529 |
|
Other funds holding AZN
IA
VCM
VAM
1832 Asset Management's AZN Position: Q1 2026 in Review
1832 Asset Management increased its AstraZeneca (AZN) stake by 122% in Q1 2026, buying an estimated $67.8M and bringing the position to 641,315 shares worth $126M. The position accounts for 0.12% of the portfolio, ranked #137.
1832 Asset Management first reported a position in AZN in Q1 2014 and has held it in 49 quarters since. The position peaked at $223M in Q2 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- 1832 Asset Management held 641,315 shares of AstraZeneca worth $126M as of Q1 2026.
- 1832 Asset Management bought 351,790 AstraZeneca shares in Q1 2026, an estimated $67.8M.
- AstraZeneca made up 0.12% of 1832 Asset Management's portfolio in Q1 2026, its #137 holding.
- 1832 Asset Management first reported a position in AstraZeneca in Q1 2014 and has held it in 49 quarters since.
- 1832 Asset Management's AstraZeneca position peaked at $223M in Q2 2022.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.